Physician profile
John Testa
NPI 1609835735
$9,127.36
in general payments reported to CMS, 2019-2025
27 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.91 · 2020: $1,024 · 2021: $595 · 2022: $3,214 · 2023: $2,003 · 2024: $1,617 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,254.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,887.67 | 2020-2024 | Glassia, Hyqvia, Trintellix |
| Abbvie INC. | $1,169.81 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,076.44 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $736.93 | 2021-2025 | |
| Lilly USA, LLC | $630.36 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $407.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $333.70 | 2020-2025 | Freestyle Libre 3 |
| Amgen INC. | $288.81 | 2019-2025 | Repatha, Otezla, Evenity |
| Antares Pharma, INC. | $188.79 | 2022-2025 | Xyosted |
| Glaxosmithkline, LLC. | $172.22 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $145.45 | 2020 | |
| Intuitive Surgical, INC. | $134.84 | 2025 | |
| Pfizer INC. | $110.52 | 2023-2024 | |
| Cequr Corporation | $110.19 | 2022-2023 | Cequr Simplicity |
| Baxter Healthcare | $103.91 | 2025 | Tisseel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.45 | 2020-2024 | Jardiance |
| Amarin Pharma, INC. | $82.50 | 2020 | |
| Merck Sharp & Dohme LLC | $79.76 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Scilex Pharmaceuticals INC. | $74.81 | 2020-2025 | |
| Dexcom, INC. | $68.98 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $67.32 | 2020-2023 | Veozah |
| Axsome Therapeutics, INC. | $50.03 | 2024 | Auvelity |
| Amneal Pharmaceuticals LLC | $31.12 | 2024 | Unithroid |
| Idorsia Pharmaceuticals US INC | $30.88 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $19.82 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $18.35 | 2020 | |
| Tolmar, INC. | $16.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Testa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.